{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1235.350",
  "meta" : {
    "versionId" : "6",
    "lastUpdated" : "2023-08-08T01:00:54.000-04:00",
    "profile" : ["http://hl7.org/fhir/StructureDefinition/shareablevalueset",
    "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]
  },
  "extension" : [{
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
    "valueString" : "B.well Connected Health Author"
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
    "valueDate" : "2023-08-08"
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
    "valueDate" : "2023-08-08"
  }],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.350",
  "identifier" : [{
    "system" : "urn:ietf:rfc:3986",
    "value" : "urn:oid:2.16.840.1.113762.1.4.1235.350"
  }],
  "version" : "20230808",
  "name" : "COVID19Vaccine_EventClinicalGrouping",
  "title" : "COVID19 Vaccine_Event Clinical Grouping",
  "status" : "active",
  "date" : "2023-08-08T01:00:54-04:00",
  "publisher" : "B.well Connected Health Steward",
  "description" : "b.well created value set by Sr. Clinical Business Analyst for the COVID19 Vaccine_Event Clinical Grouping.",
  "jurisdiction" : [{
    "extension" : [{
      "url" : "http://hl7.org/fhir/StructureDefinition/data-absent-reason",
      "valueString" : "UNKNOWN"
    }]
  }],
  "purpose" : "(Clinical Focus: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Data Element Scope: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Inclusion Criteria: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Exclusion Criteria: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.)",
  "compose" : {
    "include" : [{
      "valueSet" : ["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.345"]
    },
    {
      "valueSet" : ["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.346"]
    },
    {
      "valueSet" : ["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.348"]
    },
    {
      "valueSet" : ["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.349"]
    }]
  },
  "expansion" : {
    "identifier" : "urn:uuid:cbc860d0-9969-4319-ab15-4f27771f8daa",
    "timestamp" : "2023-09-26T09:51:02-04:00",
    "total" : 129,
    "offset" : 0,
    "parameter" : [{
      "name" : "count",
      "valueInteger" : 1000
    },
    {
      "name" : "offset",
      "valueInteger" : 0
    }],
    "contains" : [{
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0001A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0001A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0002A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0002A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0003A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0003A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0004A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0004A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; booster dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0011A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0011A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0012A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0012A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0013A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0013A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; third dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0021A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; first dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0022A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; second dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0031A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; single dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0031A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage; single dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0034A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; booster dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0034A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage; booster dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0041A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; first dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0041A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0042A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; second dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0042A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0051A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0051A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; first dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0052A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0052A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; second dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0053A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0053A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; third dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0054A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0054A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; booster dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0064A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0064A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25mL dosage, booster dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0071A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0071A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; first dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0072A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0072A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; second dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0073A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0073A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; third dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0074A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0074A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0081A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0081A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; first dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0082A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0082A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; second dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0083A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0083A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, third dose (6 months through 4 years)"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0091A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0091A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sarscov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, preservative free, 50 mcg/0.5 ml dosage; first dose, when administered to individuals 6 through 11 years"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0092A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0092A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sarscov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, preservative free, 50 mcg/0.5 ml dosage; second dose, when administered to individuals 6 through 11 years"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0093A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0093A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sarscov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, preservative free, 50 mcg/0.5 ml dosage; third dose, when administered to individuals 6 through 11 years"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0094A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; booster dose, when administered to individuals 18 years and over"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0094A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0104A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0111A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0111A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0112A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0112A",
      "display" : "Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0113A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0113A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, preservative free, 25 mcg/0.25 ml dosage; third dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0124A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0124A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, bivalent spike protein, preservative free, 30 mcg/0.3 ml dosage, tris-sucrose formulation, booster dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0144A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0144A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrnalnp, spike protein, bivalent, preservative free, 25 mcg/0.25 ml dosage, booster dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "0154A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "0154A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, bivalent spike protein, preservative free, 10 mcg/0.2 ml dosage, diluent reconstituted, tris-sucrose formulation, booster dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "code" : "0164A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "code" : "0173A",
      "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "207",
      "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "208",
      "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "210",
      "display" : "SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "211",
      "display" : "SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL dose"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "212",
      "display" : "SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "217",
      "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "218",
      "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "219",
      "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "221",
      "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "227",
      "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 50 mcg/0.5 mL dose"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "228",
      "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 25 mcg/0.25 mL dose"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "229",
      "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 50 mcg/0.5 mL or 25 mcg/0.25 mL dose"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "230",
      "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "2468235",
      "display" : "SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "2470234",
      "display" : "SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML Injectable Suspension"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "2479835",
      "display" : "SARS-COV-2 (COVID-19) vaccine, vector - Ad26 100000000000 UNT/ML Injectable Suspension"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "300",
      "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "301",
      "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "302",
      "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "502",
      "display" : "SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN)"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "506",
      "display" : "SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA), CanSino Biological Inc./Beijing Institute of Biotechnology"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "510",
      "display" : "SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm)"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "511",
      "display" : "SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac)"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "518",
      "display" : "SARS-COV-2 COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "519",
      "display" : "SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna"
    },
    {
      "system" : "http://hl7.org/fhir/sid/cvx",
      "version" : "20230725",
      "code" : "520",
      "display" : "SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTech"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91300",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91300",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91301",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91301",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91302",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91303",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91303",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91304",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91304",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91305",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91305",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91306",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91306",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91307",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91307",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91308",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91308",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91309",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91309",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91310",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91311",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91311",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91312",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91312",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid19]) vaccine, mrna-lnp, bivalent spike protein, preservative free, 30 mcg/0.3 ml dosage, trissucrose formulation, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91313",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91313",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid19]) vaccine, mrna-lnp, spike protein, bivalent, preservative free, 50 mcg/0.5 ml dosage, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91314",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91314",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, bivalent, preservative free, 25 mcg/0.25 ml dosage, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "version" : "2023",
      "code" : "91315",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2023",
      "code" : "91315",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, bivalent spike protein, preservative free, 10 mcg/0.2 ml dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "code" : "91316",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use"
    },
    {
      "system" : "http://www.ama-assn.org/go/cpt",
      "code" : "91317",
      "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use"
    }]
  }
}